Hematologist-oncologists Corey Cutler, MD, MPH, and Hana Safah, MD, discuss how graft-vs-host disease presents and the importance of early intervention.
This article will appear in the January 2024 issue of Evidence-Based Oncology.™ Each year, our January issue features a recap of proceedings from the American Society of Hematology Meeting and Exposition.
"The findings suggest that early detection and management of vitiligo lesions can be improved by estimating the likelihood of its development in transplant recipients."
The high-precision cell therapy Orca-T demonstrated high rates of relapse-free survival, overall survival, and graft-vs-host disease RFS at 1 year, as well as a low incidence of GVHD in patients with intermediate- to high-risk myelodysplastic syndrome.
Ehab L. Atallah, MD, highlights updates in chronic lymphocytic leukemia, emphasizing the importance of understanding the plethora of options that are present for oncologists treating patients within this population.